Atopic dermatitis, also known as eczema, is a non-contagious inflammatory skin condition. It is a chronic disease characterized by dry, itchy skin that can weep clear fluid when scratched. People with eczema also may be particularly susceptible to bacterial, viral, and fungal skin infections.
Why Is the Study of Eczema (Atopic Dermatitis) a Priority for NIAID?
Eczema, or atopic dermatitis, is an inflammatory skin condition that affects an estimated 30 percent of the U.S. population, mostly children and adolescents. It is a chronic disease characterized by dry, itchy skin that can weep clear fluid when scratched. People with eczema also may be particularly susceptible to bacterial, viral, and fungal skin infections.
How Is NIAID Addressing This Critical Topic?
NIAID conducts and supports basic research in allergy and immunology that increases our understanding of the immune system and how it contributes to the development of atopic dermatitis and its complications. NIAID also funds patient-centered research to explore the genetic determinants of eczema and to evaluate new strategies to prevent and treat the disease.
Latest News Releases
NIAID Now Blog
- NIAID Recognizes October as Eczema Awareness Month
October 17, 2022
- Common Skin Bacteria Found Beneficial Against Drying, Aging
February 4, 2022
Related Public Health and Government Information
To learn about risk factors for eczema, different types of eczema and current prevention and treatment strategies visit the National Library of Medicine page on eczema.